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How did the study come about?
According to World Health Organization (WHO) esti-
mates, 33.4 million people were infected with the
human immunodeficiency virus (HIV) type 1 globally
at the end of 2008.1 Sub-Saharan Africa and Asia are
the two regions that have the highest HIV prevalence,
with 22.4 and 4.7 million people infected, respect-
ively.1 During the 5 years prior, access to combination
antiretroviral therapy (ART) in low- and middle-
income countries increased 10-fold to reach 4 million
people, providing coverage to 28% of those in need.2
Several studies have reported significant reductions in
HIV-related morbidity and mortality for individuals
with access to treatment in these regions.3–5 In
resource-limited settings, to facilitate the rapid expan-
sion of access to ART, WHO recommends a standar-
dized, public-health approach.6 This is in contrast to
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the individualized patient-management strategies in
developed countries, based on routinely available
diagnostic monitoring.7 Standardized first-line ART
regimens consist of a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) and a dual nucleoside/
nucleotide reverse transcriptase inhibitor (NRTI)
backbone, available in some countries as generic
fixed-dose combinations.6 Recommended second-line
regimens combine a ritonavir-boosted protease inhibi-
tor (PI) with two previously unused and/or recycled
NRTIs.6
Routine HIV viral-load monitoring is not generally
available in resource-limited countries and treatment
failure is frequently identified based on immunologic-
al definitions and/or the occurrence of clinical events.6
Virological breakthrough may be detected late while
the failing regimen is continued, thus facilitating the
acquisition and accumulation of drug resistance-
associated mutations.8 Drug-resistant HIV variants
may compromise the effectiveness of subsequent
lines of treatment and their transmission to newly in-
fected individuals has severe public health conse-
quences.9,10 To date, ART programmes have been
implemented without accompanying HIV drug resist-
ance (HIVDR) monitoring. Monitoring studies are
hampered by the lack of a molecular laboratory infra-
structure required for genotypic resistance testing,
logistical challenges related to maintaining specimen
integrity in remote settings and the high costs of test-
ing.11 Challenges to scaling up ART in resource-limited
countries, such as absence of routine virological moni-
toring and limited choices of drug regimen, advocate
for the development of a global public-health frame-
work to monitor and prevent the emergence of HIVDR
and thus maximize long-term ART effectiveness.12
HIV-1 subtype B is the predominant viral subtype
in North America, Western Europe and Australia,
and antiretroviral (ARV) drugs have been developed
on this subtype. However, in sub-Saharan Africa
and Asia, the genetic diversity in HIV subtypes and
circulating recombinant forms (CRFs), resulting from
recombination between subtypes within a dually in-
fected person, is extensive.13 Although current evi-
dence is limited, some reports have suggested that
the propensity to develop HIVDR and the spectrum
of mutations that emerge during drug selective pres-
sure, may differ across subtypes and CRFs.14–17 Viral
heterogeneity may, therefore, have implications for
rates of disease progression and patient response to
ART, warranting further study of inter-subtype differ-
ences in mutational pathways to resistance.
To help assess the extent of HIVDR in sub-Saharan
Africa and Asia, a collaborative bi-regional programme
was established, called LAASER [Linking African and
Asian Societies for an Enhanced Response (LAASER)
to HIV/AIDS; http://www.laaser-hivaids.org] with the
primary aim of increasing regional capacities for the
monitoring of HIVDR. PharmAccess Foundation, a
non-profit organization dedicated to the strengthening
of health systems and improving access to quality basic
health care in sub-Saharan Africa, has developed the
PharmAccess African Studies to Evaluate Resistance
(PASER). TREAT Asia (Therapeutics, Research,
Education and AIDS Training in Asia) is a network
of clinics, hospitals and research institutions working
to ensure safe and effective delivery of HIV/AIDS treat-
ment throughout the Asia-Pacific and has developed
the TREAT Asia Studies to Evaluate Resistance
(TASER). Both PASER and TASER programmes in-
corporate a monitoring and evaluation (M) and a
surveillance (S) protocol. Laboratories providing geno-
typing results for PASER and TASER are required to
participate in the TREAT Asia Quality Assurance
Scheme (TAQAS), which is an ongoing assessment
programme to build genotyping laboratory capacity,
described elsewhere.18 The focus of this cohort profile
is the monitoring and evaluation protocols, PASER-M
and TASER-M.
How are PASER and TASER
set up and how are they funded?
Through the LAASER programme, PASER and TASER
receive financial support from the Dutch Ministry of
Foreign Affairs through a partnership with Stichting
Aids Fonds, PharmAccess Foundation, TREAT Asia
(a programme of amfAR, The Foundation for AIDS
research) and International Civil Society Support.
PASER-M is coordinated by PharmAccess Foundation,
in collaboration with the Amsterdam Institute for
Global Health and Development (AIGHD) and the
Virology Department at the University Medical
Center Utrecht, The Netherlands. TASER-M is coordi-
nated by TREAT Asia and its statistical and data
management centre is the National Centre in HIV
Epidemiology and Clinical Research (NCHECR), The
University of New South Wales in Sydney, Australia.
PASER constitutes a newly established collaboration
between HIV treatment clinics, laboratories with
the capacity to perform genotypic sequencing and
research centres. Thirteen clinical sites and two
reference laboratories in six African countries
(Kenya, Nigeria, South Africa, Uganda, Zambia and
Zimbabwe) are collaborating on PASER-M (Figure
1a). Details of the PASER-M collaborating clinical
sites are summarized in Supplementary Table 1 avail-
able as Supplementary data at IJE online. Ethics ap-
provals were obtained from the Academic Medical
Center Institutional Review Board (IRB) and local
IRBs. Sites are government, non-government,
faith-based or private clinics and hospitals, situated
in major cities or urban areas. ART was introduced
at the sites at various time points between 1992 and
2006 (median: 2004). Of the 13 sites, 11 provided
drugs, consultations and routine laboratory testing
free of charge. HIV viral load testing is available at
8 of the 13 sites.
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TASER collaborating sites are selected from within
the existing TREAT Asia network, based on their la-
boratory capacity to perform genotypic sequencing, as
described elsewhere.18,19 Sites that do not have in-
ternal laboratory genotyping capacity can participate
through collaboration with a TAQAS-certified labora-
tory. Eleven clinical and laboratory sites in six Asian
countries (China, Indonesia, Malaysia, Philippines,
South Korea and Thailand) are collaborating on
TASER-M (Figure 1b). Ethics approvals were obtained
from local IRBs having Federal wide Assurances
(FWAs) in place from the United States Office for
Human Research Protections. FWAs are required for
TASER sites as they participate in the International
Epidemiologic Databases to Evaluate AIDS (IeDEA)
initiative, described elsewhere.20 Sites are generally
government- or university-based clinics and hospitals
or private clinics, situated in major cities and other
urban areas. Those with ethics approvals prior to
June 2010 are shown in Figure 1b. ART has been avail-
able in Asia for more than 10 years, even in
less-resourced countries in the region, and all
TASER-M clinical sites have on-site viral load testing.
Clinical sites follow their national guidelines to
assess eligibility for ART initiation in accordance
with the WHO recommendations.6 Genotypic resist-
ance testing on PASER and TASER clinical specimens
are performed in TAQAS-certified genotyping labora-
tories.18 Laboratories are encouraged to become ac-
credited members of the WHO/HIVResNet HIV Drug
Resistance Laboratory network.21 Population-based
nucleotide sequencing of the HIV protease (PR) and
partial reverse transcriptase (RT) gene regions is per-
formed on plasma specimens, which have HIV RNA of
more than 1000 copies/ml. Plasma is obtained from
blood collected in EDTA tubes which is locally
stored at 808C and, if required, batch-shipped on
dry ice to a genotyping laboratory.
PASER-M genotypic testing is concentrated in two
central reference laboratories and thus depends on a
robust cold-chain and web-based specimen tracking
system for managing specimen shipments. Approxi-
mately half of TASER-M clinical sites have an
on-site or local genotyping laboratory. Most genotyp-
ing laboratories amplify viral sequences using
in-house methods, based on assembled commercially
available assay components and laboratory-specific
sequencing and amplification primers. One TASER la-
boratory uses the commercial kit TruGene (Bayer
HealthCare, Tarrytown, NY, USA). The online
Stanford interpretation system is used by most labora-
tories to identify drug resistance-associated muta-
tions.22 Resistance genotyping is generally performed
retrospectively (i.e. not real-time) for all participants.
Details of the genotyping laboratories are summarized
in Supplementary Table 2 available as Supplementary
data at IJE online. PASER and TASER sequences are
submitted to the ViroScore database (Advanced Bio-
logical Laboratories SA, France) for data storage.
What do PASER-M and TASER-M
cover and who is included in
the sample?
The monitoring studies are multi-centre prospective
cohort designs with sequential patient enrolment.
Patient eligibility criteria are listed in Table 1. The
main study objectives are to assess prevalence and
incidence of HIVDR, mutational patterns and factors
associated with HIVDR in persons initiating first-line
ART or switching to a second-line regimen due to
treatment failure under routine circumstances.
Participants are required to sign informed consent
prior to study enrolment and must initiate or switch
ART within 30 days (PASER-M) or 181 days
(TASER-M) following baseline specimen collection.
Regimen switch due to treatment failure may be
determined clinically, as assessed by disease progres-
sion, immunologically, by CD4 cell count or virologic-
ally, by HIV viral load. A single drug substitution,
due to toxicity or intolerance, is not considered a regi-
men switch. Each site aims to recruit a total of 240
participants. Second-line participants are recruited
among first-line participants failing therapy and
the clinical site patient population. The recom-
mended maximum site-specific enrolment period is
18 months.
How often are participants
followed-up? What data are
being collected?
Participants are followed-up as per local standard of
care guidelines. The frequency of follow-up visits for
patients varies by site (range: every 1–6 months). The
studies make use of clinical data collected during rou-
tine visits and recorded in medical records. HIV viral
load measurement and, if the HIV RNA value is more
than 1000 copies/ml, genotypic resistance testing is
performed on plasma specimens taken at baseline,
prior to regimen switch due to treatment failure and
at annual follow-up. For patients failing a first-line
regimen, the treatment failure data collection be-
comes the new baseline for the second-line regimen.
Annual follow-up is then calculated from this point.
For patients failing a second-line ART, the treatment
failure data collection is the final assessment prior to
the patient going off study.
PASER-M clinical data are recorded on standardized
hard-copy data forms, which are completed at
3-monthly intervals and entered in a web-based clin-
ical data system, called the HAART Monitoring
System. PharmAccess performs quality assurance
measures, which include (i) source data verification
during 3- to 6-monthly site audits, (ii) checks to iden-
tify data entry inconsistencies or suspect data values
and (iii) specimen tracking. TASER-M site personnel
extract clinical data from site databases and medical
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Figure 1 Geographical location of (a) PASER-M collaborating sites and (b) TASER-M collaborating sites
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records collected as part of usual care. From March
2008 to March 2009, TASER-M data were submitted
electronically to NCHECR on a quarterly basis, as part
of study start up, then at 6-monthly intervals. At each
transfer, NCHECR performs quality assurance meas-
ures, which include (i) checks to identify data entry
inconsistencies or suspect data values, (ii) specimen
tracking and (iii) ARV history completeness.
Annually, a random 10% of TASER-M patients are
selected for internal site audit where submitted data
are compared with patient medical records.
The studies capture standardized virological and
genotypic data at protocol determined intervals.
Genotyping data consist of HIV subtype and HIVDR
mutations, including insertions and deletions.
TASER-M also records discordant subtypes, i.e.
when the PR and RT region subtypes differ.
Laboratory specimen tracking information is recorded
during specimen processing, allowing assessment of
pre-analytical and assay validity. Genotyping labora-
tories complete an annual laboratory survey that
includes the dynamic range of the virological assay
used, the regions of PR and RT genome routinely
sequenced and the interpretation algorithm used.
Observational patient data includes demographic par-
ameters, physical measures, Centres for Disease
Control and Prevention (CDC) class (TASER-M) or
WHO clinical stage (PASER-M), serology of hepatitis
and syphilis (TASER-M), opportunistic infections,
current ART regimen, ARV history, concomitant medi-
cations, routine laboratory parameters (including CD4
counts) and assessment of drug adherence. Main ana-
lyses will include age, sex, ethnicity, HIV exposure
category, WHO clinical stage (PASER-M) or CDC
class (TASER-M), viral hepatitis co-infection status,
CD4 count, HIV viral load, HIV subtype, drug adher-
ence, ARV history and ART regimen as covariates.
Predictors of drug resistance will be assessed using
logistic regression models. Incidence of drug resist-
ance will be summarized using person-years methods
and Kaplan–Meier plots. Cox proportional hazards
models will be used to assess risk factors associated
with developing drug resistance.
What is the anticipated attrition?
The actual attrition in PASER-M and TASER-M
cannot currently be accurately estimated because the
duration of follow-up in the databases is still limited.
In sub-Saharan Africa patient retention in routine
ART programmes has been estimated at 61.623 to
66.8%2 at 24 months on ART, attrition being mainly
due to loss of follow-up and early death.23 Therefore,
in PASER-M, the original site-specific sample size was
calculated accounting for 20% loss to follow-up and
25% mortality after 24 months. Attrition is expected
to vary between sites as a result of differences in pa-
tient populations, care provided and provisions for
tracing lost to follow-up. TASER-M sites are generally
sourced from the ongoing TREAT Asia HIV
Observational Database (TAHOD).19 Loss to follow-up
for TAHOD was 6.9/100 person-years for the
12-month period from September 2007 to September
2008. Since TASER-M monitors specified outcomes,
we speculate that TASER-M follow-up will be similar
to TAHOD or better.
What has been found?
PASER-M
Patient recruitment commenced in March 2007 and
was completed in September 2009. Of the 13 sites,
12 reached the site-specific target of 240 participants,
enrolling a total of 3005 participants. Excluding pa-
tients with protocol violations (n ¼ 16) and key data
missing (n ¼ 4), 2985 patients were included in the
analysis. Of these, 2736 (91.6%) were eligible for a
first-line ART regimen and 249 (8.3%) were eligible
for second-line ART due to treatment failure. Patient
characteristics are summarized in Table 2. For
first-line patients, the median age was 36.8 years
[inter-quartile range (IQR) 31.3–42.6] and 58% were
women. HIV exposure was predominantly reported as
heterosexual contact. More than 60% had advanced
disease (classified as WHO stages III or IV) and 37%
had pre-therapy CD4 counts of less than 100 cells/ml.
Across all 13 sites, median baseline CD4 counts of
Table 1 Patient eligibility criteria for PASER-M and
TASER-M
Inclusion criteria
Confirmed HIV-1 infection
518 years of age
Eligiblea for initiation of a first-line ART regimen or
switch from a first-line ART regimen (containing at
least three antiretroviral drugs and taken for 56 months)
to a second-line ART regimen due to virological,
immunological and/or clinical failure
Signed informed consent for study participation prior
to enrolment
Exclusion criteria
Currently taking ART (minimum of three-drug regimen),
if initiating a first-line ART regimenb
Pregnancy at enrolmentc
HIV-1/2 dual infection (in endemic countries only)c
aEligibility for ART initiation defined in accordance with na-
tional ART guidelines (i.e. advanced immunodeficiency as
defined by CD4 cell count less than 200 or less than 350 cells/
ml, or advanced clinical disease according to WHO clinical stage/
CDC classification).
bSpecified PASER-M definition: re-initiation of a first-line ART
regimen <30 days after stopping previous first-line ART (pre-
vious use of antiretroviral prophylaxis or mono/dual therapy is
not an exclusion criterion).
cExclusion criteria applicable to PASER-M only.
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first-line patients were less than 200 cells/ml (site
median 135 cells/ml, range 93–191). Median baseline
HIV viral load was 4.9 log10 copies/ml (IQR 4.2–5.5).
The most frequently prescribed first-line regimens
were based on NNRTIs (99.7%), i.e. efavirenz (EFV)
and nevirapine (NVP) at 60 and 40%, respectively.
First-line dual NRTI backbones were predominantly
lamivudine (3TC)/zidovudine (AZT) (37%), emtricita-
bine (FTC)/tenofovir (TDF) (34%) and 3TC/stavudine
(d4T) (26%). Overall, 67% of patients started a
3TC-containing first-line regimen. Among patients
initiating first-line ART, 95% (n¼ 2 598) reported to
be ARV-naive and 5% (n¼ 138) had previous ARV
experience, which included ART (n¼ 60), mono/dual
therapy (n¼ 6), single-dose NVP for prevention of
mother-to-child transmission of HIV (PMTCT)
(n¼ 35), combination therapy for PMTCT (n¼ 19),
and unspecified (n¼ 22). Compared with ARV-naive
first-line patients, ARV-experienced first-line patients
had higher median CD4 counts (177 vs 133 cells/ml,
P< 0.0001), were younger (median 34.7 vs 37.0
years, P< 0.0001) and were more likely to be female
(76.1 vs 57.5%; P< 0.001). Other baseline charac-
teristics did not differ between ARV-naive and
ARV-experienced patients.
For the 249 (8.3%) patients switching to second-line
ART, the median age was 38.6 years (IQR 32.9–44.2)
and sex was equally distributed. HIV exposure was pre-
dominantly heterosexual contact and 48% of patients
had advanced disease (classified as WHO stages III or
IV). Median CD4 count was 125 cells/ml (IQR 46–196).
Median pre-switch HIV viral load was 4.1 log10 copies/
ml (IQR 3.2–5.0). Ritonavir-boosted lopinavir (LPV)
was the PI used almost exclusively (98%).
As shown in Table 3, analysis of the first available
1795 viral sequences demonstrated that the most
common HIV subtypes in the cohort were C (1216,
68.7%), A (338, 18.7%) and D (179, 10.0%). The
first PASER report published in 2008 reviewed the
available data on HIVDR in sub-Saharan Africa.11
Baseline HIVDR data from Lusaka, Zambia, has re-
cently been published.24 International presentations
have summarized preliminary baseline HIVDR muta-
tions and subtype distributions.25,26
TASER-M
Patient recruitment commenced in March 2007 and
for the March 2009 transfer, seven sites from
Thailand, Hong Kong and Malaysia provided data.
Of 773 patients, 755 (97.7%) commenced ART
within 181 days of baseline specimen collection and
728 (96.4%) participants had genotypic data available.
Of these, 693 (95.2%) ARV-naive patients and 10
(1.4%) ARV-experienced patients, following prior
PMTCT, were eligible for first-line regimens. A further
25 (3.5%) patients were eligible for second-line ART
following first-line treatment failure. Patient charac-
teristics are summarized in Table 2. For ARV-naive
first-line patients, the median age was 36.5 years.
Almost two-thirds of patients were male and HIV ex-
posure was predominantly heterosexual contact. More
than one-third of patients were classified as CDC class
C and almost half of the patients had pre-therapy
CD4 counts less than 100 cells/ml. Median baseline
HIV viral load was 5.0 log10 copies/ml (IQR 5.4–6.8)
and the most common first-line regimens were based
on NNRTIs (85.6%). Excluding 14 (2.4%) patients on
a randomized clinical trial with a blinded NNRTI
Table 3 HIV subtypes and circulating recombinant formsa by region and country
PASER-M (Africa) TASER-M (Asia)b
Total
South
Africa Zambia Uganda Kenya Nigeria Zimbabwe Thailand
Hong
Kong Malaysia
n (%) 2523 (100.0) 624 (24.7) 583 (23.1) 410 (16.3) 140 (5.5) 21 (0.8) 17 (0.7) 542 (21.5) 111 (4.4) 75 (3.0)
A 340 (13.6) 2 (0.3) 4 (0.7) 235 (57.3) 97 (69.1) 1 (4.8) 1 (0.2)
B 114 (4.5) 3 (0.5) 37 (7.0) 55 (49.5) 19 (25.3)
C 1236 (49.2) 617 (98.9) 571 (97.9) 9 (2.2) 19 (13.6) 17 (100.0) 2 (1.8) 1 (1.3)
D 179 (7.1) 1 (0.2) 1 (0.2) 160 (39.0) 17 (12.1)
G 11 (0.4) 2 (0.3) 1 (0.2) 2 (1.4) 6 (28.6)
CRF01_AE 585 (23.2) 485 (89.5) 52 (46.8) 48 (64.0)
CRF02_AG 20 (0.8) 1 (0.2) 3 (0.5) 1 (0.2) 14 (66.7) 1 (0.2)
Other recombinants
or discordant
subtypes
32 (1.3) 2 (0.3) 1 (0.2) 2 (1.4) 18 (3.3) 2 (1.8) 7 (9.3)
Unclassified 6 (0.2) 3 (0.7) 3 (2.1)
Data are n (%) of subtypes/CRFs, unless otherwise indicated. CRF, circulating recombinant form.
aHIV subtypes were determined from the pol sequences, using the REGA HIV-1 subtyping algorithm version 2.0 (http://dbpartners.
stanford.edu/RegaSubtyping) and/or Stanford HIV drug resistance database (http://hivdb.stanford.edu).
bThe collaborating sites in Philippines, South Korea and Indonesia had not yet provided sequence data at time of the current
analysis.
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component, NVP was more commonly prescribed than
EFV at 56 and 42%, respectively. First-line dual NRTI
backbones were predominantly 3TC/d4T (47%), 3TC/
AZT (29%) and 3TC/TDF (10%). For first-line PI regi-
mens, the favoured NRTI backbone was FTC/TDF
(33%) compared with 3TC/d4T (30%) or 3TC/AZT
(18%). For the ritonavir-boosted PI component, ata-
zanavir (ATZ) was only slightly favoured over LPV at
43 vs 41%, respectively. Overall, 542 (91.4%) of ARV-
naive patients started a 3TC-containing first-line regi-
men. The 10 PMTCT patients received perinatal
prophylaxis of AZT/3TC/NVP (n¼ 7), AZT (n¼ 2) or
AZT/NVP (n¼ 1) for between 14 and 102 days and
all were prescribed AZT/3TC/NVP as first-line
regimens.
For the 25 (3.4%) second-line patients, 22 (88%)
were of Thai ethnicity and the median age was 36.5
years (IQR 32.4–41.9). Females were in the majority
(64%), HIV exposure was predominantly heterosexual
(92%) and 60% of patients had experienced at least
one CDC class C event. Of 21 patients with CD4
counts available within 6 months of starting a
second-line therapy, the median CD4 count was 197
(IQR 109–299). Median pre-switch HIV viral load was
4.0 log10 copies per/ml (IQR 3.6–4.5). All patients
were on PI-based regimens, following failure on
first-line NNRTI-based regimens (median duration
30.3 months). The most commonly prescribed PI com-
ponent was ritonavir-boosted LPV (88%).
As shown in Table 3, from analysis of the 728 avail-
able viral sequences, the most common subtypes were
CRF01_AE (584, 80.2%) and subtype B (111, 15.2%).
Non-CRF01_AE recombinants were identified in eight
(1.1%) patient specimens. For 21 (2.9%) specimens,
the subtype differed between PR and RT regions, sug-
gesting dual infection or recombination. International
presentations have summarized 2009 baseline HIVDR
mutations and subtype distributions.27,28
Complete baseline and prospective outcome data for
PASER-M and TASER-M are anticipated to become
available in 2010–13.
What are the main strengths
and weaknesses?
Programmes that monitor national and regional levels
of primary and secondary HIVDR contribute to
evidence-based recommendations to inform treatment
guidelines and provide feedback on the success of HIV
treatment and prevention programmes. PASER and
TASER, with TAQAS, are developing capacity in
sub-Saharan Africa and the Asia-Pacific for coordi-
nated HIVDR monitoring and genotypic laboratory
testing. The study protocols are harmonized with the
WHO HIV Drug Resistance Prevention Survey proto-
col.29 An important strength is the large number of
patients and sites participating, representing a diverse
spectrum of patient populations, clinic types, ART
regimens and HIV subtypes. Opportunities exist to in-
vestigate the impact of drug resistance on HIV natural
history, rates of disease progression and response to
treatment in non-B subtypes. Data from genotypic re-
sistance testing will also provide insight into the
population genetics and dynamics of transmitted
HIVDR in the region.
PASER-M and TASER-M have several limitations.
First, patient samples at each site are not necessarily
representative of the site, country or region. Second,
data quality depends on the completeness of clinical
information captured through routine patient care. In
PASER-M, data may have been collected under vary-
ing conditions, since some sites had no or limited re-
search experience at study initiation. Third, at some
sites, study initiation was delayed by several months
due to the time required for contract negotiation, IRB
study approval and, in TASER-M, procurement of
FWAs. After study initiation, recruiting the required
number of patients within the recommended
18-month period proved difficult for some sites, due
to asymptomatic patients not seeking care or treat-
ment, cost of medication or low-prevalence in their
setting. Fourth, HIVDR monitoring activities in
resource-limited countries in sub-Saharan Africa are
limited by high costs of laboratory testing. To address
this challenge, PASER has initiated a public–private
consortium, called Affordable Resistance Test for
Africa (ART-A), which aims to develop affordable
test algorithms for the detection and interpretation
of HIVDR for use in laboratories and clinics (http://
www.arta-africa.org).
How can I collaborate? Where
can I find out more?
Ownership of individual site data remains with the
contributing site. Sites are represented by their prin-
cipal investigators on the respective PASER and
TASER Steering Committees. Research is to be the
subject of peer-reviewed publications and analysis
priorities are driven by a concept sheet process. Both
studies accept concept proposals from external re-
searchers for review, if submitted in collaboration
with one or more of the site principal investigators.
The PASER and TASER protocols contribute data
under the LAASER partnership (http://www.laaser
hivaids.org) and TASER also contributes data to
IeDEA.20 Collaborating sites are also encouraged to
make an appropriate subset of their data available
to Ministry of Health in their respective countries in
order to contribute to local efforts in monitoring
HIVDR. Questions regarding participation, research
concepts or requests for data should be sent to
Tobias Rinke de Wit, email: t.rinkedewit@
pharmaccess.org (PASER), or Thida Singtoroj, email:
thida.singtoroj@treatasia.org (TASER).
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Supplementary Data
Supplementary Data are available at IJE online.
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